Thrombocytopenia induced by nalidixic acid
Over the years the Netherlands Centre for Monitoring of Adverse Reactions to Drugs has received six case reports on patients with profound but transient thrombocytopenia probably induced by nalidixic acid (Negram, Mictral) . The table gives the details of these patients.
Cases
Characteristically thrombocytopenia developed within 10 to 15 days of treatment with nalidixic acid, 4 g daily, and rapidly recovered after stopping the drug (table). All patients had platelet counts below 30 x 109/1 and serious impairment of blood coagulation, haemorrhagic symptoms being recorded in five. In one case immediate relapse of thrombocytopenia on rechallenge with a single dose of 1 g nalidixic acid provided the proof for a causal relation. One patient concomitantly had a generalised rash. The bone marrow was studied in two patients and showed active megakaryopoiesis.
Comment
Case observations on patients with thrombocytopenia induced by nalidixic acid do not appear to have been described. The rare occurrence of thrombocytopenia is, however, briefly mentioned in the data sheet on Negram (in the Netherlands, but not in Britain) and in the sixth edition of The Pharmacological Basis of Therapeutics.' According to a report from the Australian Drug Evaluation Committee three cases of thrombocytopenia suspected to be induced by nalidixic acid were reported there during 1964-71.' The Committee on the Safety of Medicines has been notified of eight similar cases (J C P Weber, personal communication, 1984) .
Apart from the positive result on rechallenge in one patient, several observations suggest a causal relation with nalidixic acid-in particular the rapid and complete recovery when the drug was discontinued. In two patients underlying disturbances of haematopoieses were excluded by examination of bone marrow. Urinary tract infections are not known to be associated with thrombocytopenia. No other suspected drugs than nalidixic acid were known to have been used. Although no specific tests were done, the induction time of 10 to 15 days, the rapid recovery, the active bone marrow, and the concomitant rash in one patient are consistent with an allergic reaction resulting in peripheral destruction of platelets. Nalidixic acid is excreted mainly by the kidneys, and it may be relevant that five of these patients were over 65 and that two of them had clearly impaired renal function.
It is concluded that the use of nalidixic acid is associated with the risk of developing sudden and severe thrombocytopenia. Although this reaction seems to be rare, there may have been considerable underreporting. The notification of similar occurrences to national drug authorities is recommended. 
